EXTON, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Isolagen, Inc. has reorganized and emerged from bankruptcy as Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on developing regenerative fibroblast cells for aesthetic, medical and scientific applications. The Company has named a new Board of Directors. The Food and Drug Administration (FDA) is currently reviewing the biologics license application (BLA) for Fibrocell Science's lead therapy, azfibrocel-T (formerly Isolagen Therapy), in development to treat nasolabial fold wrinkles. Azfibrocel-T is the sole topic for discussion at the Cellular, Tissue and Gene Therapies Advisory Committee Meeting on October 9, 2009 in Bethesda, MD.
Fibrocell Science, Inc. Names New Board of Directors
Fibrocell Science, Inc. has appointed a new Board of Directors and named David Pernock as chairman. Mr. Pernock joins Fibrocell Science with extensive commercial experience, most recently as senior vice president, Pharmaceuticals and Vaccines at GlaxoSmithKline. New Fibrocell Science board members named to date are Paul A. Hopper, managing director of Cappello Group, who has more than 20 years experience in international public company markets -- primarily in the medical, healthcare and biotechnology sectors; Kelvin D. Moore, consultant sales director for Seaborne Group with extensive experience in project leadership, business strategy, finance, business consultancy, new ventures, management and executive development; and Robert S. Langer, Ph.D., professor, chemical & biomedical engineering, Massachusetts Institute of Technology, and distinguished leader in the field of biomedical engineering.
Declan Daly, who was instrumental in the company's reorganization and had served as an executive at Isolagen, will continue to lead Fibrocell Science as interim chief executive officer (CEO). The Board intends to name a CEO in the near future, and at that time, Dec
|SOURCE Fibrocell Science, Inc.|
Copyright©2009 PR Newswire.
All rights reserved